Oenon Holdings, Inc. Financial Summary for the Third Quarter of the Fiscal Year Ending December 2026 (Japanese GAAP) (Consolidated)

Performance Overview

For the cumulative third quarter, net sales were 65,066 million yen (Year-over-Year 3.0% increase), operating income was 3,244 million yen (4.2% increase), ordinary income was 3,274 million yen (1.1% increase), and quarterly net income attributable to owners of parent was 2,395 million yen (2.4% increase), maintaining a trend of rising profits. By segment, the company comprises alcoholic beverages, enzyme pharmaceuticals, real estate, and others; notably, enzyme pharmaceuticals contributed to revenue and profit growth due to strong overseas sales and expanded contract fermentation. The full-year forecasts have been revised to net sales of 89,000 million yen, ordinary income of 4,000 million yen, and net income of 3,250 million yen. The execution of a share buyback was also disclosed.

Outlook and Impact on Shareholders

Taking into account the revision of the full-year forecast and expected gains on sales of investment securities, the year-end net income outlook was increased by 350 million yen (to 3,250 million yen). The company intends to continue efforts to achieve the mid-term plan "NEXT100." The implementation of the share buyback is regarded as part of shareholder returns and may help mitigate dilution pressure. Segment-wise, continued overseas expansion of enzyme pharmaceuticals and the enlargement of contract fermentation are expected to remain drivers of profitability.